In a Phase IIb trial, hospitalised COVID-19 patients treated with desidustat did not develop acute respiratory distress syndrome (ARDS).
List view / Grid view
Filter the results
Through COVAX, doses of the Pfizer-BioNTech vaccine will be provided at a not-for-profit price for 92 low- and lower-middle-income countries.
AbbVie's RINVOQ (upadacitinib) has been approved in the EU to treat adult patients with active psoriatic arthritis (PsA).
Following Phase I results, Merck will discontinue its development of V590 and V591, two COVID-19 vaccine candidates.
Interim data from 1,000 hospitalised patients with moderate COVID-19 symptoms shows that full doses of heparin can improve patient outcomes and could reduce ICU burden.
Treatment with XPro1595 for three months caused significant changes in neurodegeneration, synaptic function and neuroinflammation.
NICE has recommended that the CAR T-cell therapy Tecartus be given to patients with relapsed or refractory mantle cell lymphoma.
The FDA has approved Aurinia Pharmaceuticals' LupkynisTM(voclosporin) for the treatment of lupus nephritis, alongside standard-of-care.
The global stockpile will provide developing countries responding to Ebola outbreaks with doses of the approved single-dose Ebola vaccine, rVSV∆G-ZEBOV-GP, live, free of charge.
Reports have said five people have been killed in a fire at the Serum Institute of India, where the Oxford-AstraZeneca COVID-19 vaccine is being made.
The approval of Cabenuva (cabotegravir and rilpivirine, injectable formulation) means HIV infected adults could receive once-monthly injections to manage their condition.
The President of the US, Joe Biden, has written a letter to the UN announcing his intention for the country to remain a part of the WHO.
A novel algorithm shows that there is a robust network for transferring plasmids between bacteria which may be causing the rapid spread of antibiotic resistance.
Research has demonstrated that the Pfizer and BioNTech COVID-19 vaccine can neutralise the B.1.1.7 variant in pre-clinical studies.
The trial will primarily assess whether alisporivir (Debio 025) can significantly reduce COVID-19 viral load in hospitalised COVID-19 patients with moderate symptoms.